Polymorphic forms of (S)-1-cyanobutan-2-yl (S)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) phenyl) ethylcarbamate

Details for Australian Patent Application No. 2006249921 (hide)

Owner Vertex Pharmaceuticals Incorporated

Inventors Blythe, Todd A.; Vlahova, Petinka

Agent Cullen & Co

Pub. Number AU-A-2006249921

PCT Pub. Number WO2006/127909

Priority 60/684,644 26.05.05 US

Filing date 25 May 2006

Wipo publication date 30 November 2006

International Classifications

C07D 263/32 (2006.01) Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings

A61K 31/421 (2006.01) - 1,3-Oxazoles, e.g. pemoline, trimethadione

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

10 January 2008 PCT application entered the National Phase

  PCT publication WO2006/127909 Priority application(s): WO2006/127909

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006249925-Modulation of LMW-PTPase expression

2006249911-(R)-N-methylnaltrexone, processes for its synthesis and its pharmaceutical use